Every few weeks one of our China lawyers gets a somewhat frantic email from an English teacher in China and we hate them.
Forming a company in China is almost always difficult and expensive. Operating a company in China is also almost always difficult and expensive.
In recent years, several large multinational pharmaceutical companies have been found to be in violation of the Anti-Unfair Competition Law.
When Christmas is approaching, China counterfeiting goes into overdrive, and this year has been no different.
Last Friday, China’s 15-month-long bribery investigation into British multinational pharmaceutical GlaksoSmithKline (GSK) ended after a one-day trial in which the court found GSK’s local subsidiary guilty of bribing doctors and hospitals and fined the company $490 million.
China presents foreign manufacturers with many paradoxes.
Just read a post on the China Leadership Blog, entitled, Why China Hiring Background Checks: We now have 15 reasons.
Pretty much since we started this blog, we have written posts that essentially set forth the following mantra.
Our last post introduced how regulations around foreign investment in China’s hospitals are changing, with the most recent announcement of seven WFOE pilots as evidence of these changes. Experienced China watchers easily recognize what is happening: China has acknowledged that it has a problem which only foreign expertise and capital can fix.